These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24227984)

  • 1. Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.
    Jiang K; Brownstein S; Sekhon HS; Laurie SA; Lam K; Gilberg S; Britton W
    Saudi J Ophthalmol; 2013 Jul; 27(3):187-92. PubMed ID: 24227984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.
    Liu S; Liu X; Wang T; Zeng C; Ren B; Yu X; Xu M; Li W; Qiao Z; You C; Yang Q; Chen M
    Front Oncol; 2022; 12():789941. PubMed ID: 35433411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.
    Wang W; Wu W; Zhang Y
    Medicine (Baltimore); 2016 Jul; 95(30):e4221. PubMed ID: 27472693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.
    Singh N; Kulkarni P; Aggarwal AN; Mittal BR; Gupta N; Behera D; Gupta A
    Medicine (Baltimore); 2012 Jul; 91(4):179-194. PubMed ID: 22732948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    Chun SG; Choe KS; Iyengar P; Yordy JS; Timmerman RD
    Cancer Biol Ther; 2012 Dec; 13(14):1376-83. PubMed ID: 22986231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
    Alì G; Proietti A; Niccoli C; Pelliccioni S; Borrelli N; Giannini R; Lupi C; Valetto A; Bertini V; Lucchi M; Mussi A; Fontanini G
    Lung Cancer; 2013 Aug; 81(2):297-301. PubMed ID: 23664446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to crizotinib in a non-small-cell lung cancer patient harboring an
    Aguado C; Gil MD; Yeste Z; Giménez-Capitán A; Teixidó C; Karachaliou N; Viteri S; Rosell R; Molina-Vila MA
    Onco Targets Ther; 2018; 11():1117-1120. PubMed ID: 29535536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
    Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
    Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review.
    Duan X; Zhao X; Wang S
    Ann Palliat Med; 2021 May; 10(5):5797-5807. PubMed ID: 32819126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
    Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
    BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
    Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
    Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.